Torfil 2.5/Torfil 10/Torfil 20

Tadalafil

Erectile dysfunction in adult males. Torfil 2.5 Benign prostatic hyperplasia in adult males.

Torfil 2.5 Erectile dysfunction & benign prostatic hyperplasia 5 mg daily at same time each day w/o regard to timing of sexual activity. Benign prostatic hyperplasia w/ finasteride therapy initiation 5 mg once daily for 26 wk. Patient w/ CrCl <30-50 mL/min 5 mg based on individual response. Torfil 10/Torfil 20 20 mg prior to anticipated sexual activity. Max daily dosing frequency: 1 tab.

May be taken with or without food: 2.5 mg tab: Swallow whole.

Hypersensitivity. Patients taking any form of organic nitrates. Torfil 2.5 Not recommended for concomitant use w/ guanylate cyclase (GC) stimulator.

Not recommended in patients w/ cardiac diseases for whom sexual activity is inadvisable. Administer nitrate at least 48 hr after last dose of tadalafil if administration is deemed necessary for life-threatening situation. Prolonged erection. Patients w/ risk factors to priapism (sickle cell anemia, multiple myeloma, or leukemia) & anatomical deformation of penis (angulation, cavernosal fibrosis or Peyronie's disease); bleeding disorders or significant active peptic ulceration. Co-administration w/ α-1 blockers (eg, doxazosin); alcohol. Discontinue medication if vision impairment occurs as this may be a sign of NAION (non-arteritic anterior ischemic optic neuropathy); sudden hearing loss occurs. Contraindicated in patients w/ known hereditary degenerative retinal disorders (eg, retinitis pigmentosa). Not recommended in combination w/ other agent for treatment of erectile dysfunction. No protection against STD. Consideration to patients w/ other urological conditions prior to initiating treatment for BPH. Not recommended for patients w/ CrCl <30 mL/min or on hemodialysis & severe hepatic impairment. May affect ability to drive & use machines. Not recommended for childn <18 yr. Not indicated for use by women.

Headache. Myalgia. Torfil 2.5 Upper abdominal pain. GERD, nausea, vomiting, arthralgia & muscle spasm. Torfil 10/Torfil 20 Dyspepsia. Back pain, flushing & nasal congestion.

Increased exposure w/ CYP 3A4 inhibitors (eg, ketoconazole, erythromycin, itraconazole & grapefruit juice). Reduced exposure w/ CYP3A4 inducers (eg, rifampicin, carbamazepine, phenytoin & phenobarb). Reduced rate of absorption w/o modifying tadalafil exposure w/ antacids (eg, Mg &/or Al hydroxide). Co-administration of tadalafil & nizatidine reduces gastric pH. Increases the hypotensive effects of nitrate. May likely increase the exposure w/ HIV PIs. Additive effect on BP w/ α-blockers (eg, doxazosin, tamsulosin & alfuzosin). Potentiates the BP-lowering effects of selected antihypertensive agents (eg, amlodipine, ARBs, enalapril, & metoprolol). Increased potential of orthostatic signs & symptoms w/ alcohol (≥5 units).

Drugs for Erectile Dysfunction & Ejaculatory Disorders / Drugs for Bladder & Prostate Disorders

G04BE08 - tadalafil ; Belongs to the class of drugs used in erectile dysfunction.

Rx